Literature DB >> 10405705

The tetracyclines.

J D Smilack1.   

Abstract

The tetracyclines, among the first of the antibiotics to become available 50 years ago, remain widely used. Tetracyclines have bacteriostatic activity against a wide variety of pathogens that are responsible for many common and some exotic infections. They are particularly valuable in the treatment of atypical pneumonia syndromes, chlamydial genital infections, rickettsial infection (Rocky Mountain spotted fever, typhus, Q fever), Lyme disease, and ehrlichiosis. On the basis of pharmacokinetic considerations, doxycycline is the preferred agent among the tetracycline congeners. Minocycline may have a limited role in the treatment of methicillin-resistant staphylococcal disease in situations in which an oral antimicrobial agent may be appropriate. The tetracyclines are generally contraindicated during pregnancy and childhood because of their association with dental staining and interference with bone growth. Photosensitivity may occur with some tetracyclines, and several drug and food interactions may limit gastrointestinal absorption.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10405705     DOI: 10.4065/74.7.727

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  34 in total

1.  The Advantage of Bactericidal Drugs in the Treatment of Infection.

Authors:  Jeffrey Alder; Barry Eisenstein
Journal:  Curr Infect Dis Rep       Date:  2004-08       Impact factor: 3.725

2.  Potential role of Veillonella spp. as a reservoir of transferable tetracycline resistance in the oral cavity.

Authors:  D Ready; J Pratten; A P Roberts; R Bedi; P Mullany; M Wilson
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

3.  Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo.

Authors:  Gilson C N Franco; Mikihito Kajiya; Tadashi Nakanishi; Kouji Ohta; Pedro L Rosalen; Francisco C Groppo; Cory W O Ernst; Janie L Boyesen; John D Bartlett; Philip Stashenko; Martin A Taubman; Toshihisa Kawai
Journal:  Exp Cell Res       Date:  2011-03-21       Impact factor: 3.905

Review 4.  Microglia Function in Central Nervous System Development and Plasticity.

Authors:  Dorothy P Schafer; Beth Stevens
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-07-17       Impact factor: 10.005

5.  Case Series: Minocycline-Associated Thyroiditis.

Authors:  Kate Millington; Alexandra Charrow; Jessica Smith
Journal:  Horm Res Paediatr       Date:  2019-09-18       Impact factor: 2.852

6.  Randomized Trial of Clarithromycin for Mediterranean Spotted Fever.

Authors:  Esperança Anton; Tomas Muñoz; Francisco Javier Travería; Gemma Navarro; Bernat Font; Isabel Sanfeliu; Ferran Segura
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

7.  Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy.

Authors:  Omero Alessandro Paoluzi; Giovanna Del Vecchio Blanco; Emanuela Visconti; Manuela Coppola; Carla Fontana; Marco Favaro; Francesco Pallone
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

8.  Controlled drug release for oral condition by a novel device based on ethylene vinyl acetate (EVA) copolymer.

Authors:  S Kalachandra; Lin Dongming; S Offenbacher
Journal:  J Mater Sci Mater Med       Date:  2002-01       Impact factor: 3.896

9.  Antibiotic susceptibilities of Anaplasma (Ehrlichia) phagocytophilum strains from various geographic areas in the United States.

Authors:  Max Maurin; Johan S Bakken; J Stephen Dumler
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

10.  Does doxycycline work in synergy with cisplatin and oxaliplatin in colorectal cancer?

Authors:  Jayesh Sagar; Kevin Sales; Sas Dijk; JanWillem Taanman; Alexander Seifalian; Mark Winslet
Journal:  World J Surg Oncol       Date:  2009-01-06       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.